Tarsus Pharmaceuticals (Nasdaq: TARS) has agreed to acquire Alkeus Pharmaceuticals, a privately held retinal disease biotech, for approximately USD 450 million upfront and up to USD 350 million in additional milestones, bringing the total potential deal value to USD 800 million. The asset is gildeuretinol (ALK-001), a once-daily oral small molecule in Phase III development for Stargardt disease — an inherited retinal dystrophy affecting more than 36,000 clinically diagnosed patients in the US, with no FDA-approved therapy.
The upfront consideration is structured as USD 270 million in cash and USD 180 million in Tarsus common stock, priced at USD 61.38 per share. Milestones of up to USD 350 million are tied to regulatory approval and first commercial sale, without granular breakdown between the two triggers. Former Alkeus shareholders will also receive low single-digit tiered royalties on future sales, an uncommon feature in a full acquisition that preserves long-term participation in the asset's commercial success.
The deal is Tarsus's second retinal acquisition in under a month. In July, Tarsus acquired iRenix Medical for up to USD 565 million, bringing in IRX-101, an investigational ocular antiseptic for patients receiving intravitreal therapy. The Alkeus deal adds a second, mechanistically distinct platform — oral visual cycle modulation — rather than extending Tarsus's existing lotilaner franchise. The February 2026 appointment of former Allergan CEO David Pyott to the Tarsus board preceded both acquisitions; Allergan built its ophthalmology dominance through serial acquisition of differentiated assets.
Tarsus simultaneously announced an oversubscribed USD 125 million private placement, reinforcing the balance sheet to fund the USD 270 million cash consideration. The financing follows continued commercial growth of XDEMVY, which generated USD 173.9 million in Q2 2026 sales.